Split verdict on COVID boosters
CDC panel recommendation would dial back FDA’s EUA, which itself was pared back from Pfizer’s request
A CDC advisory committee rendered a split verdict on FDA’s emergency use authorization of a booster dose of Pfizer’s Comirnaty COVID-19 vaccine, agreeing that it should be available to the elderly and those at risk of severe COVID-19, but rejecting the agency’s contention that it should be available to individuals at occupational risk.
The recommendation reinforces the idea that the goal of COVID-19 vaccines should be to prevent severe disease and death, not to produce sterilizing immunity or keep workers on the job. ...